Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001).

Authors :: Coveler, Andrew L.
Gutierrez, Martin
Vaccaro, Gina M.
Brown-Glaberman, Ursa
Grilley-Olson, Juneko E.
Kindler, Hedy L.
Zalupski, Mark
Heath, Elisabeth I.
Piha-Paul, Sarina A.
Wehr, Allison
Lu, Hailing
Hayman, Jonathan
Bajor, David L
Source :: Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, p708-708, 1p
Publication Year :: 2023

Full Text Access

Tools